Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Breast Neoplasms 34Ovarian Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Prostatic Neoplasms 2Neoplasms by Site 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Advanced Solid Tumors 2Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Solid Tumor, Adult 1Neoplasm Metastasis 1Melanoma 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1HR+/HER2- Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Ductal, Breast 1Brain Neoplasms 1

Interventions

Injections 13toripalimab 12pembrolizumab 4atezolizumab 4Gemcitabine 4Carboplatin 4Cisplatin 3trastuzumab deruxtecan 2tislelizumab 2spartalizumab 2lenvatinib 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Fluorouracil 2Albumin-Bound Paclitaxel 2talazoparib 1sintilimab 1penpulimab 1olaparib 1niraparib 1nedaplatin 1mirdametinib 1enfortumab vedotin 1conteltinib 1Nivolumab 1Magnetic Resonance Spectroscopy 1Leucovorin 1Letrozole 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Solid Tumor × Fulvestrant × Clear all
NCT04282031 2024-08-07

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Beta Pharma (Suzhou) Co., Ltd.

Phase 1/2 Recruiting
224 enrolled
BreastOther solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡